Zydus Knocked Back On Farxiga In US As Brand Continues To Grow
US Court Finds Key Patent Is Not Invalid As Obvious
Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.
